76
I’m so grateful that @japanairlinesJP requires masking in the airplane and at airports 🙏🏼
Taking off to Tokyo to celebrate the winners of the Maria Sklodowska-Curie Prize for young female scientists 👩🏻🔬
77
In conclusion, VOCs do not evolve to further escape from CD8 T beyond the ancestral SARS-CoV-2 virus. The virus uses multiple pathways to inhibit MHC I. If one is missing, others compensate. Given this, CD8 T cell-based therapeutic approaches may be difficult for COVID-19. (End)
78
CD8 T cells help fight off viral infection by detecting and killing infected cells. CD8 T cells detect MHC I + viral peptide on infected cells. One of the common tricks viruses use to avoid killing is to inhibit MHC I expression and presentation. (2/)
pubmed.ncbi.nlm.nih.gov/19498380/
79
In this study, @MiyuMoriyama et al investigate how well SARS-CoV-2 variants of concern (VOC) suppress MHC I needed for recognition by cytotoxic T cells. This question is important to understand how well the virus limits CD8 killing 🧵(1/) @biorxivpreprint
biorxiv.org/content/10.110…
80
Q: Why can nasal vaccines do?
A:“Nasal sprays assemble a separate set of antibodies known as immunoglobulin A (IgA). These populate the spongy mucosal tissues of the nose, mouth and throat, where the COVID-causing coronavirus first lands." #PrimeandSpike
By @mvbroadfoot twitter.com/sciam/status/1…
81
So excited to launch the new Center for Infection & Immunity @YaleCII at @YaleMed!! This center will investigate fundamental mechanisms of infection and immunity that hold key to better prevention, diagnosis and treatment of wide range of diseases. (1/)
medicine.yale.edu/cii/
82
Thank you @ASlavitt for speaking up about #longCOVID 🙏🏼 We need a lot more public attention, research, therapy and drugs to combat this debilitating disease. We also need similar attention/resources/research/treatment for #MECFS that results after infection with other pathogens. twitter.com/ASlavitt/statu…
83
A Phase 2 clinical trial of oral camostat mesylate during early phase of COVID-19 in outpatients reduced illness course (including fatigue) and prevented loss of smell and taste!
Work of fantastic colleagues at @YaleMed. (1/)
medrxiv.org/content/10.110…
84
An excellent piece on why we should be looking to nasal spray as the future of COVID booster vaccines by @Carolynyjohnson
@NIAIDNews please include our Prime and Spike in the upcoming vaccine bake-off 🥺
washingtonpost.com/health/2022/04…
85
Very important work by @PGTimmune and colleagues showing that repeated SARS-CoV-2 antigen exposure (infection and/or vaccines) does not lead to an exhausted T cell phenotype.
#GetBoosted
nature.com/articles/s4159… twitter.com/PGTimmune/stat…
86
This new preprint by Stadler et al. integrated data from 37 randomized controlled trials to ask how the timing and dose of passive antibodies (monoclonal Ab & convalescent plasma) predict protection from SARS-CoV-2 disease. A short 🧵 (1/)
medrxiv.org/content/10.110…
87
Check out our latest review on the immunology and immunopathology of COVID-19 (both acute and #longCOVID). So fortunate to work with brilliant #womeninSTEM on this review - my #shero friends @MiriamMerad @blish_lab @sallustolab 💪🏼
science.org/doi/10.1126/sc…
88
What immune cell features are most predictive of COVID outcomes?
@mkuchroo @JcsHuang Patrick Wong et al used ML algorithm Multiscale PHATE to assign each immune cell type in COVID patients a mortality-likelihood score. Latest from @KrishnaswamyLab 💪🏼 (1/)
go.nature.com/3K0QCqi
89
“COVID toes” are swollen discolored toes (and fingers) that were seen in areas with high incidence of COVID-19, but the cause is unknown. This new study by @JeffGehlhausen et al shows lack of association between covid toes and SARS-CoV-2 infection. 🧵(1/)
pnas.org/content/119/9/…
90
So truly honored to be named a @Yale Sterling Professor 🙏🏼
medicine.yale.edu/news-article/i…
91
We need your help for some crucial #LongCOVID research! If you live in the New York area, have FULLY recovered from COVID-19 infection and it has been AT LEAST 12 weeks since you were first sick, please email us at prcovid@mountsinai.org @PutrinoLab
RT highly appreciated 🙏🏼
92
The latest summary of “How Long Covid Exhausts the Body” by @joshkellerjosh. Visual journalism at its best 👀
Happy to contribute insights with @nathavindra. Ft. @PutrinoLab @michelle_monje @microbeminded2 @Survivor_Corps @itsbodypolitic & patients.
nytimes.com/interactive/20…
93
Nasal Spray Booster Keeps COVID-19 at Bay - an excellent piece by Meghan Rosen.
So grateful to @HHMINEWS for stepping up and supporting our research efforts on COVID - on acute COVID, #longCOVID pathogenesis and vaccine strategies against SARS-CoV-2 🙏🏼
hhmi.org/news/nasal-spr…
94
Omg 🤩
Our Prime and Spike 👃🏼 vaccine story is in the @RollingStone 👩🏻🔬
By @daxe with comments from @BenIsraelow
rollingstone.com/culture/cultur…
95
The intranasal spike protein booster will also be much easier to administer (via nasal spray), quite stable (just protein) and is much more likely to be accepted by people who are hesitant of mRNA or those with needle phobia. (16/)
96
To elicit mucosal immunity from scratch, live attenuated vaccines are often necessary, due to the need to introduce sufficient antigen and innate immune signals needed for priming via mucosal surfaces. Live vaccines are not safe for immunocompromised. (3/)
nature.com/articles/s4157…
97
Current COVID vaccines are given intramuscularly. This induces robust circulating antibodies and systemic T & B cell responses that block viral spread and disease. However, to better block infection, immunity has to be established at mucosal surfaces. (2/)
annualreviews.org/doi/10.1146/an…
98
Vaccines that reduce infection & disease are needed to combat the pandemic. Here, @tianyangmao @BenIsraelow et al. describe our new mucosal booster strategy, Prime and Spike, to induce such immunity via nasal delivery of unadjuvanted spike vaccine 🧵 (1/)
biorxiv.org/content/10.110…
99
I highly recommend this very informative thread posted by @michelle_monje on this study. twitter.com/michelle_monje…
100
This study also opens up all kinds of questions and possibilities. For example, therapies that can 1) block inflammatory cytokines, 2) block inducers of such cytokines, or 3) reset reactive microglia can be considered for future clinical trials. Thank you for reading till end.
We study innate and adaptive immunity against viruses and study disease pathogenesis. #COVID19 #longCOVID #vaccines @HHMINEWS @YaleIBIO @YaleMed @YaleCII